SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Marberger Michael) "

Search: WFRF:(Marberger Michael)

  • Result 1-3 of 3
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Schmitz-Draeger, Bernd J., et al. (author)
  • Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance : The WHO/ICUD Consensus
  • 2015
  • In: Urologia internationalis. - : S. Karger AG. - 0042-1138 .- 1423-0399. ; 94:1, s. 1-24
  • Research review (peer-reviewed)abstract
    • Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role.in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.
  •  
2.
  • Andriole, Gerald L, et al. (author)
  • Effect of dutasteride on the risk of prostate cancer.
  • 2010
  • In: The New England journal of medicine. - 1533-4406. ; 362:13, s. 1192-202
  • Journal article (peer-reviewed)abstract
    • We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease.
  •  
3.
  • Cuzick, Jack, et al. (author)
  • Prevention and early detection of prostate cancer.
  • 2014
  • In: The Lancet Oncology. - 1470-2045 .- 1474-5488. ; 15:11, s. e484-92
  • Journal article (peer-reviewed)abstract
    • Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-3 of 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view